All News

puzzle.RA_.jpg

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials

Mrinalini Dey, MD

Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this dissociation between biological disease control and patient-reported outcomes.

Read Article
nurse,appointment,vitals

Nurse-Led Treat-to-Target Clinics

EurekAlert!

New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy outcomes in autoinflammatory disease

EurekAlert!

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health.

Read Article
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

Jiha Lee, MD

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.

Read Article
From Domains to Decisions: Personalizing PsA Care with Data At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj
Dr. John Cush RheumNow ( View Tweet)
Using Combination csDMARDs in PsA Dr. Eric Ruderman shares his insights on abstracts OP0093, OP0106, and POS0106, which discuss the effectiveness of combination csDMARD therapy, long-term outcomes of methotrexate and leflunomide, and a real-world treat-to-target strategy in https://t.co/Pv4YEyYShm
Dr. John Cush RheumNow ( View Tweet)
Social Determinants of Health in SLE SDH, such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, https://t.co/Xf2bR7ap5m
Dr. John Cush RheumNow ( View Tweet)
What is the difference between difficult to treat, and treatment-refractory? (see these criteria for PsA) Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going #EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY

Links:

David Liew drdavidliew ( View Tweet)
Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology don’t have organized care for them. A call to action from Patrick Kiely, to do better by these patients #EULAR2025 @RheumNow https://t.co/h3Zvov642L

Links:

David Liew drdavidliew ( View Tweet)
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢! German national Bechterew-App RCT of App based intervention AXIA, control group was standard of care 200pts 12wks ASAS20 response 51% vs. 9% ASAS40 response rate 23% vs. 3% BASDAI:

Aurelie Najm AurelieRheumo ( View Tweet)

The key changes for the new 2025 EULAR recommendations on RA treatment #EULAR2025 @RheumNow https://t.co/dp5LnoFdpW

Links:

David Liew drdavidliew ( View Tweet)
EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent disease (inflammation is mandatory) + 4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI #EULAR2025 @RheumNow https://t.co/8nx26mWX3C

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Self-management of rheum disease is ripe for apps, gamification. How well does it work though? This app (Axia) in axSpA was basically as good as a biologic. Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that #EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89

Links:

David Liew drdavidliew ( View Tweet)
#RA #recommendations #update Some recommendations were merged For sure some regions will consider #Combination #csDMARDs or Switch to another 👇🤔 #sulfasalazine #leflunomide Depends on access, pt preference, disease activity/severity #EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV

Links:

Janet Pope Janetbirdope ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Leaky pipeline in rheumatology: In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men. Top reasons? 🚫 Unfair promotion 🚫 Poor communication 🚫 No career path Workplace equity still lags. POS0407 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

Recommendations for RA management at #EULAR2025 - MTX [or other csDMARDs] and steroids still remain the first line- nothing beats that! - ofcourse minimize steroids! - rather than stopping meds at remission, reducing doses may be a better solution. Not much changed. @RheumNow https://t.co/NK5ejsgjWV

Links:

Bella Mehta bella_mehta ( View Tweet)
Proud to present the 1st #ARCH_ArLAR prospective interventional study #EULAR2025 Large awareness campaign ➡️ 🔺️Proportion new referred CIRDs pts ⬆️ from 31 to 37% 🔺️Time 2 see a rheuma ⬇️ 14 to 10 mo 🔺️Time 2 diagnosis ⬇️ 18 to 12 mo POS1310 @RheumNow @ArLARheumatolog https://t.co/eKrRKHNXMZ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

The transformative potential of integrating ePROMs into AI care pathways 🔺️Study by Dr Antoni Chan et al. achieved a new-to-followup ratio of 1:2.5 outperforming the national average of 1:4.2 🔺️Without losing contact with pts @synovialjoints POS1271 #EULAR2025 @RheumNow https://t.co/z3jO3ADHR1

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×